| P2860 | cites work | Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression | Q73317622 |
| | Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group | Q73688073 |
| | Practice guideline for the treatment of patients with bipolar disorder (revision) | Q95789383 |
| | The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence | Q22241870 |
| | Psychosocial Disability in the Course of Bipolar I and II Disorders | Q22253033 |
| | Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications | Q24649095 |
| | Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy | Q24657384 |
| | Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up | Q28182929 |
| | Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial | Q28259736 |
| | Effectiveness of adjunctive antidepressant treatment for bipolar depression | Q28295408 |
| | The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS | Q28570728 |
| | Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise | Q28575082 |
| | Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen | Q29616224 |
| | Hippocampal volume and depression: a meta-analysis of MRI studies | Q30974294 |
| | A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. | Q33844681 |
| | The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study | Q33850634 |
| | Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression | Q33949128 |
| | Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials | Q33975437 |
| | Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. | Q33979161 |
| | The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death | Q34076866 |
| | Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants | Q34211475 |
| | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | Q34275783 |
| | Antidepressants for bipolar depression: a systematic review of randomized, controlled trials | Q34344394 |
| | Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication | Q34424321 |
| | Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials | Q34456077 |
| | Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania | Q34552561 |
| | Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). | Q34564599 |
| | A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents | Q34568810 |
| | Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments | Q34622392 |
| | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations | Q34631235 |
| | Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders | Q34635329 |
| | Stress, depression, and neuroplasticity: a convergence of mechanisms | Q34686632 |
| | Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials | Q34749757 |
| | Mood state at study entry as predictor of the polarity of relapse in bipolar disorder | Q35985601 |
| | Maintenance therapies in bipolar disorder: focus on randomized controlled trials | Q36210974 |
| | Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials | Q36466463 |
| | Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program | Q36630487 |
| | Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials | Q36778511 |
| | Maintenance treatment in bipolar disorder: a focus on aripiprazole | Q36902005 |
| | Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo | Q38394215 |
| | Treatment of depression in bipolar disorder: new directions for research. | Q40720720 |
| | The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. | Q40970988 |
| | Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. | Q42556936 |
| | Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania | Q42608014 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. | Q42613693 |
| | A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. | Q42625302 |
| | A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group | Q42626284 |
| | Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder | Q43593933 |
| | Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 |
| | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety | Q44045819 |
| | Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 |
| | A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder | Q44275529 |
| | Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial | Q44299951 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 |
| | Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study | Q44495168 |
| | Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects | Q44545444 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Suicide risk in bipolar disorder during treatment with lithium and divalproex | Q44586528 |
| | Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone | Q44824135 |
| | Causal relationship between stressful life events and the onset of major depression | Q44861459 |
| | Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic | Q45220527 |
| | A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. | Q45931601 |
| | The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 |
| | A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 |
| | Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study | Q46669710 |
| | Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes | Q46775574 |
| | Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. | Q46881170 |
| | Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone | Q46921502 |
| | Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials | Q46984808 |
| | Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. | Q47207451 |
| | Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. | Q48481499 |
| | Subgenual prefrontal cortex abnormalities in mood disorders | Q48725544 |
| | Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs | Q48886408 |
| | Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. | Q48943191 |
| | A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. | Q50278208 |
| | Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. | Q50772431 |
| | Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. | Q51948101 |
| | Factors Influencing the Incidence of Lamotrigine-Related Skin Rash | Q57274025 |
| | Partial Normalization of Serum Brain-Derived Neurotrophic Factor in Remitted Patients after a Major Depressive Episode | Q59389009 |
| P433 | issue | 5 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 391-402 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Primary Care Companion to the Journal of Clinical Psychiatry | Q15751574 |
| P1476 | title | Easing the burden of bipolar disorder: from urgent situations to remission | |
| P478 | volume | 10 | |